Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Dermatology · Basal Cell Carcinoma

Understanding Subtypes and Risk Levels

At a Glance

Basal cell carcinoma risk depends on the tumor’s growth pattern plus its size, location, borders, recurrence history, immune status, prior radiation, and whether it grows along a nerve. These features help doctors choose treatment and assess whether the tumor was fully removed.

When you receive a pathology report for Basal Cell Carcinoma (BCC), you will see terms describing its subtype and location. Doctors use these details, alongside clinical features like size, to perform risk stratification—a process of determining how likely the tumor is to return after treatment and how difficult it will be to completely remove [1][2]. Your risk level (Low Risk vs. High Risk) is not based on just one factor, but on how your tumor’s biology interacts with its size, location, and your overall health [1].

Understanding Your Subtype

The “subtype” refers to the growth pattern of the cancer cells as seen under a microscope. Some patterns are well-defined, while others are “aggressive” and grow in unpredictable ways [3][4].

Lower-Risk Subtypes

  • Nodular: The most common type. It usually grows as a solid, well-defined “nodule” or lump [5]. Because it is often self-contained, it is typically easier to remove completely [6].
  • Superficial: This type grows horizontally along the top layer of the skin rather than deep into the tissue [5]. While it can cover a large area, it is generally considered lower-risk [6].

Note: Nodular and superficial tumors are not automatically low-risk if they are large, recurrent, or located in sensitive areas.

High-Risk (Aggressive) Subtypes

These patterns are more difficult to treat because they often have microscopic extensions that go beyond what the doctor can see with the naked eye [7][8].

  • Infiltrative: These cells grow in thin, jagged strands that “infiltrate” or weave into healthy tissue, making it hard to find the true edge of the tumor [5][3].
  • Micronodular: Similar to nodular, but the bundles of cells are tiny and scattered, which increases the risk that some might be left behind during standard surgery [3][7].
  • Morpheaform (Sclerosing): This type can look like a subtle scar or thickened patch of skin [9]. It is biologically aggressive and can cause significant local tissue damage if not treated thoroughly [9].
  • Basosquamous: This is generally considered a more aggressive variant that shares features of both BCC and squamous cell carcinoma. It carries a higher recurrence risk and some increased metastatic potential compared to conventional BCC, and often requires specialist management [3][10].

The Importance of Location (Guideline Zones)

Guidelines, such as those from the National Comprehensive Cancer Network (NCCN), categorize the body into areas based on treatment difficulty and recurrence risk [1][11].

Zone Body Areas Included
Area H The “Mask” of the face (nose, eyelids, eyebrows, lips, chin), ears, genitalia, hands, and feet.
Area M The cheeks, forehead, scalp, neck, and shins.
Area L The trunk (chest/back) and the rest of the arms and legs.

How Risk is Assessed

To determine if your BCC is “High Risk,” your doctor looks at a combination of features [1][11]. Guideline size thresholds act as aids rather than absolute rules, generally based on the largest clinical diameter:

  1. In Area H: Any tumor, regardless of size, is often treated as high-risk because of the sensitive nature of the anatomy [11][12]. This doesn’t automatically mandate Mohs surgery, but often prefers complete margin assessment.
  2. In Area M: A tumor is typically considered high-risk if it is 10mm (1cm) or larger in diameter [11].
  3. In Area L: A tumor is typically considered high-risk if it is 20mm (2cm) or larger in diameter [11].

Other High-Risk Factors: Regardless of size or location, your BCC may be classified as high-risk if you have a suppressed immune system, if the tumor has recurred after previous treatment, if it grew in an area of prior radiation, if it has poorly defined borders, or if it shows perineural invasion (growing along a nerve) [13][3][14]. Identifying these factors early allows your care team to choose an effective treatment to ensure the best possible outcome [15][16].

Common questions in this guide

What does the subtype on my BCC pathology report mean?
The subtype describes the growth pattern of the cancer cells under a microscope. Nodular and superficial patterns are generally lower risk, while infiltrative, micronodular, morpheaform, and basosquamous patterns tend to be more aggressive. The subtype is only one part of the overall risk assessment.
How do my BCC's size and location affect its risk?
Doctors use guideline zones to interpret size: Area H includes the mask of the face, ears, hands, feet, and genitalia; Area M includes the cheeks, forehead, scalp, neck, and shins; and Area L includes the trunk and remaining arms and legs. A tumor is often considered high risk at any size in Area H, at 10 mm or more in Area M, and at 20 mm or more in Area L. These thresholds are aids for clinical judgment, not automatic rules.
What other findings can make basal cell carcinoma high risk?
A BCC may be high risk if the immune system is suppressed, the tumor has returned after earlier treatment, it developed in an area that received radiation, its borders are poorly defined, or it shows perineural invasion. Perineural invasion means the tumor is growing along a nerve. These findings can increase the chance of recurrence or make complete removal more difficult.
Does a high-risk BCC always require Mohs surgery?
No. High-risk features often lead doctors to consider treatment that checks the tumor margins carefully, but they do not automatically require Mohs surgery. The recommendation depends on the tumor's subtype, size, location, borders, previous treatment, and your overall health.
What does perineural invasion mean on a BCC report?
Perineural invasion means cancer cells are growing along or around a nerve. It is a high-risk finding because it can make complete removal more difficult and may change the treatment plan. Ask your dermatologist or surgeon how this result affects your care.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on skin basal cell carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my pathology report, which specific histological subtype do I have, and is it considered an 'aggressive' growth pattern?
  2. 2.Is the location of my BCC considered an 'Area H' zone, and how does that affect the treatment plan?
  3. 3.How do my tumor's size, location, and border definition together determine my overall risk for recurrence?
  4. 4.Was there any evidence of perineural invasion or ill-defined borders found during my biopsy?
  5. 5.Given my risk level, why is the recommended treatment the best choice for me?

References

References (16)
  1. 1

    Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma.

    Chen OM, Kim K, Steele C, et al.

    Cancers 2022; (14(15)) doi:10.3390/cancers14153720.

    PMID: 35954384
  2. 2

    Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

    Bichakjian CK, Olencki T, Aasi SZ, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2016; (14(5)):574-97 doi:10.6004/jnccn.2016.0065.

    PMID: 27160235
  3. 3

    Histologically Agressive Basal Cell Carcinoma With Particular Emphasis On Galeal Infiltration Of The Scalp.

    Requena C, Serra-Guillén C, Sanmartín O

    Actas dermo-sifiliograficas 2022; (113(6)):575-582 doi:10.1016/j.ad.2022.01.026.

    PMID: 35339267
  4. 4

    Basal cell carcinoma: clinical and pathological features.

    Di Stefani A, Chimenti S

    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2015; (150(4)):385-91.

    PMID: 26099353
  5. 5

    Line-field confocal optical coherence tomography of basal cell carcinoma: a descriptive study.

    Suppa M, Fontaine M, Dejonckheere G, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2021; (35(5)):1099-1110 doi:10.1111/jdv.17078.

    PMID: 33398911
  6. 6

    Frequent Occurrence of High-Risk Basal Cell Carcinoma in Xeroderma Pigmentosum: A Histopathological Insight From an Indian Cohort.

    Imran S, Dagar S, Ahuja R, et al.

    Journal of cutaneous pathology 2025; (52(2)):154-161 doi:10.1111/cup.14753.

    PMID: 39529253
  7. 7

    Non-Melanoma Skin Cancer Tumor's Characteristics and Histologic Subtype as a Predictor for Subclinical Spread and Number of Mohs Stages required to Achieve Tumor-Free Margins.

    Santos-Arroyo A, Carrasquillo OY, Cardona R, et al.

    Puerto Rico health sciences journal 2019; (38(1)):40-45.

    PMID: 30924914
  8. 8

    The importance of superficial basal cell carcinoma in a retrospective study of 139 patients who underwent Mohs micrographic surgery in a Brazilian university hospital.

    Takata Pontes L, Fantelli Stelini R, Cintra ML, et al.

    Clinics (Sao Paulo, Brazil) 2015; (70(11)):721-5.

    PMID: 26602517
  9. 9

    Clinical and Molecular Features of Morpheaform Basal Cell Carcinoma: A Systematic Review.

    Conte S, Ghezelbash S, Nallanathan B, Lefrançois P

    Current oncology (Toronto, Ont.) 2023; (30(11)):9906-9928 doi:10.3390/curroncol30110720.

    PMID: 37999140
  10. 10

    [The role of dermoscopy in the diagnosis of basosquamous carcinoma].

    Elmahi H, Lahlou A, Baybay H, et al.

    The Pan African medical journal 2016; (25()):252 doi:10.11604/pamj.2016.25.252.11345.

    PMID: 28293368
  11. 11

    Metastatic basal cell carcinoma: Case series and literature review.

    Rodrigues MG, de Lucena AV, Domingues GA, et al.

    Brazilian journal of otorhinolaryngology 2025; (91 Suppl 1()):101619 doi:10.1016/j.bjorl.2025.101619.

    PMID: 40441022
  12. 12

    Adequacy of surgical margins, re-excision, and evaluation of factors associated with recurrence: a retrospective study of 769 basal cell carcinomas.

    Gürsel Ürün Y, Can N, Bağış M, et al.

    Anais brasileiros de dermatologia 2023; (98(4)):449-459 doi:10.1016/j.abd.2022.07.005.

    PMID: 36934062
  13. 13

    Complete Margin Assessment Versus Sectional Assessment in Surgically Excised High-Risk Keratinocyte Carcinomas: A Systematic Review and Meta-Analysis.

    Fraga SD, Besaw RJ, Murad F, et al.

    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2022; (48(7)):704-710 doi:10.1097/DSS.0000000000003462.

    PMID: 35778249
  14. 14

    Assessment of high- and low-risk histopathologic subtypes of basal cell carcinoma using artificial intelligence and dermatologist evaluation.

    Liang V, Shahrouki P, Nejad D, et al.

    JAAD international 2026; (26()):103-112 doi:10.1016/j.jdin.2026.03.014.

    PMID: 42179893
  15. 15

    Basal Cell Carcinoma.

    Heath MS, Bar A

    Dermatologic clinics 2023; (41(1)):13-21 doi:10.1016/j.det.2022.07.005.

    PMID: 36410973
  16. 16

    European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023.

    Peris K, Fargnoli MC, Kaufmann R, et al.

    European journal of cancer (Oxford, England : 1990) 2023; (192()):113254 doi:10.1016/j.ejca.2023.113254.

    PMID: 37604067

This page is for informational purposes only and does not constitute medical advice. Your dermatologist and care team should interpret your BCC subtype and risk level in the context of your complete pathology report.